Tag: diverticulitis disease market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Diverticulitis Disease Market from 2024 to 2025?

The market size for diverticulitis disease has experienced rapid expansion in recent times. The market is projected to increase from $1.85 billion in 2024 to $2.04 billion in 2025, charting a compound annual growth rate (CAGR) of 10.1%. Factors such as an ageing population, dietary patterns, obesity, and improvements in medical imaging technology contributed to the growth during the historic period.

What Is the Projected Market Size of the Diverticulitis Disease Market?

Expectations for the diverticulitis disease market point towards a significant surge in growth in the coming years. The market is projected to reach a worth of $2.92 billion by 2029, developing at a compound annual growth rate (CAGR) of 9.4%. This expected growth over the forecast period is primarily driven by factors such as colonoscopy and endoscopy, greater awareness, minimally invasive procedures, and personalized medicine. Key trends predicted for the same period include preemptive actions, improved diagnostic tools, collaborative healthcare models, and changes in healthcare policies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Who are the Major Competitors in the Diverticulitis Disease Market Outlook?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

What Is Fueling Growth in the Diverticulitis Disease Market?

The increasing addiction to smoking is predicted to boost the expansion of the diverticulitis disease market. This rise in smoking addiction is fueled by intense promotions, societal acceptability, stress, and the addictive properties of nicotine. The advent of e-cigarettes and vape devices, coupled with societal influences and peer pressure, particularly amongst young individuals, leads to an increased rate of smoking. Smoking enhances the diverticulitis disease treatment by escalating the risk of developing diverticular disease, since it restricts blood circulation to the colon and leads to severe complications, thus increasing the demand for diagnosis and treatment options. For example, in July 2022, as per Statistics Canada, a governmental agency in Canada, there was a 5.8% increase in cigarette production compared to June 2021. Also, there was a 1.3% increase in the total number of cigarettes sold from May 2022, with a count of 1.4 billion in June 2022. Hence, the growing smoking addiction is set to fuel the diverticulitis disease market. The escalating occurrences of diabetes will likely stimulate the forward momentum of the diverticulitis disease market. This increase in diabetes is majorly influenced by factors such as unhealthy diet rich in processed foods, inactive lifestyles, increased obesity rates, genetic susceptibilities, and an ageing population. Diabetes fuels the growth of the diverticulitis treatment by amplifying the risk of complications like weakened blood vessels which can make the colon more susceptible to infections and inflammation, thereby spiking the demand for treatments and therapies. For instance, in June 2024, according to The National Health Service (NHS England), a public-funded healthcare system in the UK, in 2023, the persons diagnosed as pre-diabetic by the NHS in England surged to 3,615,330, an 18% increase from 3,065,825 in 2022. Also, the number of under-40 cases jumped nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising prevalence of diabetes propels the diverticulitis disease market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Which Diverticulitis Disease Market Segments Are Growing the Fastest?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Which Industry Trends Are Shaping the Future of the Diverticulitis Disease Market?

Significant players in the diverticulitis disease market are advancing their position by creating novel medications and securing necessary approvals. The process of drug innovation can result in heightened treatment efficacy for diverticulitis, mitigation of complication risks, and enhancement of patient results. In April 2023, Seres’ microbiota drug for recurrent gut infections earned approval from the United States Food and Drug Administration, a US-focused federal establishment. This medication is engineered to tackle recurring gut infections and inhibit the reoccurrence of Clostridioides difficile (C. diff.) infections in adults who are 18 or older. The sanction of Vowst stems from a clinical trial that included 346 patients with recurrent C. diff. infection. The trial revealed that those administered with Vowst drastically had a lower likelihood of getting the infection again in comparison to those who had a placebo. The orally taken medication hinges on microbiota embedding Firmicutes spores, known to augment a robust microbiome that can ward off C. diff. settlement.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Countries Are Leading the Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

This Report Delivers Insight On:

1. How big is the diverticulitis disease market, and how is it changing globally?

2. Who are the major companies in the diverticulitis disease market, and how are they performing?

3. What are the key opportunities and risks in the diverticulitis disease market right now?

4. Which products or customer segments are growing the most in the diverticulitis disease market?

5. What factors are helping or slowing down the growth of the diverticulitis disease market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Diverticulitis Disease Market from 2024 to 2025?

The market size for diverticulitis disease has experienced rapid expansion in recent times. The market is projected to increase from $1.85 billion in 2024 to $2.04 billion in 2025, charting a compound annual growth rate (CAGR) of 10.1%. Factors such as an ageing population, dietary patterns, obesity, and improvements in medical imaging technology contributed to the growth during the historic period.

What Is the Projected Market Size of the Diverticulitis Disease Market?

Expectations for the diverticulitis disease market point towards a significant surge in growth in the coming years. The market is projected to reach a worth of $2.92 billion by 2029, developing at a compound annual growth rate (CAGR) of 9.4%. This expected growth over the forecast period is primarily driven by factors such as colonoscopy and endoscopy, greater awareness, minimally invasive procedures, and personalized medicine. Key trends predicted for the same period include preemptive actions, improved diagnostic tools, collaborative healthcare models, and changes in healthcare policies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Who are the Major Competitors in the Diverticulitis Disease Market Outlook?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

What Is Fueling Growth in the Diverticulitis Disease Market?

The increasing addiction to smoking is predicted to boost the expansion of the diverticulitis disease market. This rise in smoking addiction is fueled by intense promotions, societal acceptability, stress, and the addictive properties of nicotine. The advent of e-cigarettes and vape devices, coupled with societal influences and peer pressure, particularly amongst young individuals, leads to an increased rate of smoking. Smoking enhances the diverticulitis disease treatment by escalating the risk of developing diverticular disease, since it restricts blood circulation to the colon and leads to severe complications, thus increasing the demand for diagnosis and treatment options. For example, in July 2022, as per Statistics Canada, a governmental agency in Canada, there was a 5.8% increase in cigarette production compared to June 2021. Also, there was a 1.3% increase in the total number of cigarettes sold from May 2022, with a count of 1.4 billion in June 2022. Hence, the growing smoking addiction is set to fuel the diverticulitis disease market. The escalating occurrences of diabetes will likely stimulate the forward momentum of the diverticulitis disease market. This increase in diabetes is majorly influenced by factors such as unhealthy diet rich in processed foods, inactive lifestyles, increased obesity rates, genetic susceptibilities, and an ageing population. Diabetes fuels the growth of the diverticulitis treatment by amplifying the risk of complications like weakened blood vessels which can make the colon more susceptible to infections and inflammation, thereby spiking the demand for treatments and therapies. For instance, in June 2024, according to The National Health Service (NHS England), a public-funded healthcare system in the UK, in 2023, the persons diagnosed as pre-diabetic by the NHS in England surged to 3,615,330, an 18% increase from 3,065,825 in 2022. Also, the number of under-40 cases jumped nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising prevalence of diabetes propels the diverticulitis disease market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Which Diverticulitis Disease Market Segments Are Growing the Fastest?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Which Industry Trends Are Shaping the Future of the Diverticulitis Disease Market?

Significant players in the diverticulitis disease market are advancing their position by creating novel medications and securing necessary approvals. The process of drug innovation can result in heightened treatment efficacy for diverticulitis, mitigation of complication risks, and enhancement of patient results. In April 2023, Seres’ microbiota drug for recurrent gut infections earned approval from the United States Food and Drug Administration, a US-focused federal establishment. This medication is engineered to tackle recurring gut infections and inhibit the reoccurrence of Clostridioides difficile (C. diff.) infections in adults who are 18 or older. The sanction of Vowst stems from a clinical trial that included 346 patients with recurrent C. diff. infection. The trial revealed that those administered with Vowst drastically had a lower likelihood of getting the infection again in comparison to those who had a placebo. The orally taken medication hinges on microbiota embedding Firmicutes spores, known to augment a robust microbiome that can ward off C. diff. settlement.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Countries Are Leading the Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

This Report Delivers Insight On:

1. How big is the diverticulitis disease market, and how is it changing globally?

2. Who are the major companies in the diverticulitis disease market, and how are they performing?

3. What are the key opportunities and risks in the diverticulitis disease market right now?

4. Which products or customer segments are growing the most in the diverticulitis disease market?

5. What factors are helping or slowing down the growth of the diverticulitis disease market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the diverticulitis disease industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Diverticulitis Disease Market From 2025 To 2029?

In recent times, the market size for diverticulitis disease has seen accelerated growth. The market is projected to expand from $1.85 billion in 2024 to $2.04 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. Factors such as an aging population, obesity, changing dietary habits, and improvements in medical imaging technologies are attributed to the growth observed in the historic period.

In the coming years, the market size of diverticulitis disease is likely to undergo substantial growth, reaching a value of $2.92 billion in 2029 with a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth in the projection period include procedures like colonoscopy and endoscopy, heightened awareness, minimally invasive procedures, and personal medicine approaches. Key trends in the estimated period encompass preventive strategies, upgraded diagnostic instruments, cooperative care schemes, and alterations in healthcare policies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Diverticulitis Disease Market?

The increasing incidence of smoking addiction is predicted to spur the growth of the diverticulitis disease market in the future. Aggressive advertising, societal acceptance, stress, and nicotine’s addictive properties are driving smoking addiction rates higher. With the accessibility of e-cigarettes and vapes, alongside social impacts and peer pressure, particularly in younger generations, smoking rates are seeing a rapid increase. Increased smoking tends to amplify the growth of diverticulitis treatments as it elevates the risk of developing serious complications related to diverticular disease as it diminishes blood flow to the colon. Therefore, causing greater demand for diagnostic and therapeutic alternatives. For instance, in July 2022, as per Statistics Canada, a government agency based in Canada, cigarette production witnessed a 5.8% growth compared to June 2021. There was also a 1.3% increase in the total number of cigarettes sold from May 2022, tallying 1.4 billion in June 2022. Hence, the increasing addiction towards smoking is forecasted to stimulate the diverticulitis disease market’s growth. An increase in diabetes prevalence is foreseen as a key growth factor for the diverticulitis disease market. Factors such as unhealthy diet patterns laden with processed foods, inactive lifestyles, increased obesity numbers, genetic predispositions, and an aging demographic mainly drive the rise of diabetes. This illness intensifies the possibility of complications like weakened blood vessels, making the colon more prone to infection and inflammation, thus raising the need for treatments. For instance, The National Health Service (NHS England), a publicly funded healthcare system in the UK, reported in June 2024 that in 2023, 3,615,330 individuals were identified with pre-diabetes, an increase of 18% from 3,065,825 in 2022. Cases among those below 40 also shot up by nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Thus, the rising prevalence of diabetes is contributing to the growth of the diverticulitis disease market.

Which Segments in the Diverticulitis Disease Offer the Most Growth?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

What Are the Fastest-Growing Geographies in the Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Current Market Growth and Trends in the Diverticulitis Disease Industry?

In an effort to maintain their market prominence, leading players in the diverticulitis disease market are focused on innovating and securing approval for new drugs. This process not only enhances the efficiency of diverticulitis treatment, but it also minimizes the possibility of complications, thereby benefitting overall patient health. For instance, in April 2023, Seres’ microbiota medication for recurring gut infections received approval from the US-based federal agency, the United States Food and Drug Administration. It is intended to treat recurrent gut infections and reduce the likelihood of repeated Clostridioides difficile (C. diff.) infections in adults over the age of 18. The approval of Vowst was contingent upon a clinical trial featuring 346 patients with recurring CDI. The study found that the instances of infection recurrence were significantly lower in patients who received Vowst compared to those given a placebo. The orally administered drug centers on Firmicutes spores-containing microbiota, which are imperative for a healthy microbiome resistant to C. diff. colonization.

View the full report here:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What Are the Key Elements That Define the Diverticulitis Disease Market?

Diverticulitis disease refers to a medical condition characterized by inflammation or infection of small pouches that develop in the walls of the colon or large intestine. The symptoms of diverticular disease include lower abdominal pain, constipation, diarrhea and rectal bleeding.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theDiverticulitis Disease Market?

The growth of the diverticulitis disease market is projected to be fuelled by the escalating instances of smoking addiction. This increasing addiction is due to the aggressive marketing tactics, social acceptability of smoking, stress, and the highly addictive nature of nicotine. Young generations are also falling prey to this epidemic due to the popularity of e-cigarettes, vape devices, and peer pressure. Smoking amplifies the risk of diverticular disease by weakening the blood circulation to the colon, leading to more severe consequences and subsequently demand for medical intervention. For example, Statistics Canada reported in July 2022 that cigarette production had upped 5.8% from June 2021, with the total number of sold cigarettes increasing by 1.3% from May 2022, totaling 1.4 billion in June 2022. Thus, the growing smoking addiction will undoubtedly promote the development of the diverticulitis disease market. The escalation in instances of diabetes is another crucial contributor to the advancement of the diverticulitis disease market. Unhealthy consumption habits, increasing obesity rates, genetic factors, a sedentary lifestyle, and an aging population primarily fuel diabetes. Diabetes facilitates the rise in risks associated with diverticulitis treatment such as a weak vascular system that make the colon more vulnerable to inflammations and infections, hence enhancing the demand for treatments. Case in point, the National Health Service (NHS England) reported in June 2024 that the number of individuals diagnosed with pre-diabetes in England escalated by 18%, from 3,065,825 in 2022 to 3,615,330 in 2023. Moreover, the number of cases soared by nearly 25% in people under 40, from 173,166 in 2022 to 216,440 in 2023. Hence, the rising instances of diabetes fuel the growth of the market for diverticulitis disease.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

What is the Predicted Annual Growth Rate of theDiverticulitis Disease Market Impact Industry Trends by 2034?

The market size of diverticulitis disease has seen a swift expansion in recent years. The growth is projected to increase from $1.85 billion in 2024 to $2.04 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the growth in the historic period include an aging population, changes in eating habits, rising obesity rates, and advancements in medical imaging technologies.

The market size for diverticulitis disease is predicted to witness substantial expansion in the upcoming years. The market is projected to escalate to $2.92 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.4%. The enlargement during this period is credited to factors such as colonoscopy and endoscopy, heightened awareness, minimally invasive methodologies, and personalized medicine. The foreseeable future will see trends like precautionary methods, advanced diagnostic apparatus, cooperative care frameworks, and alterations in healthcare policies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

What Are the Current Market Growth and Trends in theDiverticulitis Disease Market That Industry Players Should Watch?

Leading firms in the diverticulitis disease market are concentrating on innovating and receiving approval for new drugs to maintain their dominance in the industry. This focus on drug invention might lead to the creation of more efficient therapies for diverticulitis, decreasing the chances of complications and enhancing patient recovery. For instance, in April 2023, the United States Food and Drug Administration, a federal organization based in the US, ratified a microbiota drug by Seres designed to treat recurrent gut infections and ward off re-infections of Clostridioides difficile (C. diff.) in adults who are 18 years and above. The approval of Vowst was rooted in a clinical trial that involved 346 patients suffering from recurrent CDI. The trial results showed that patients on Vowst had significantly lower chances of re-infection compared to those on a placebo. The orally-taken drug is composed of microbiota containing Firmicutes spores, known to enhance a healthy microbiome capable of repelling C. diff. colonization.

What Are the Major Market Players Making an Impact on theDiverticulitis Disease Market Growth?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

How Are the Key Segments of the Diverticulitis Disease Market Driving Opportunities and Innovations?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theDiverticulitis Disease Market?# Market Expansion?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Diverticulitis Disease Market 2025, By The Business Research Company:

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Antacids Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antacids-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the Diverticulitis Disease market size evolved in recent years?

The market size for diverticulitis disease has seen significant expansion in the past few years. An increase from $1.85 billion in 2024 to $2.04 billion in 2025 is anticipated, boasting a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the progress in the previous period include the aging population, eating habits, obesity, and enhancements in medical imaging.

What are the predictions for the diverticulitis disease market size in the coming years?

Robust expansion is anticipated in the diverticulitis disease market in the forthcoming years. The market size is projected to escalate to $2.92 billion by 2029, with a compound annual growth rate (CAGR) of 9.4%. The pronounced growth during the forecast period can be credited to factors such as the rise in colonoscopy and endoscopy, heightened consciousness, less invasive treatments, and personalized medical approach. Preventive steps, improved diagnostic instruments, cooperative healthcare models, and alterations in healthcare policies are key trends expected to shape the market during the forecast period.

Get your diverticulitis disease market report here!

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What key factors are fueling the growth of the diverticulitis disease market?

Advancements in the diverticulitis disease market are anticipated due to the increasing prevalence of smoking addiction. This addiction, largely promoted by aggressive marketing, societal acceptance, stress, and the addictive characteristics of nicotine, plays a significant role in the market’s expansion. The emergence of e-cigarettes and vaping devices, coupled with social influences and peer pressure among young individuals, heightens smoking rates. Smoking escalates the risk of diverticular disease by weakening the colon’s blood flow, leading to severe complications and a surge in demand for diagnosis and treatment options. For example, in July 2022, Statistics Canada, a governmental agency, reported a 5.8% increase in cigarette production compared to June 2021, while cigarette sales grew by 1.3% from May 2022 to 1.4 billion in June 2022. These trends underline how smoking addiction prevalence can directly influence diverticulitis disease market growth. A noticeable prevalence of diabetes also contributes significantly to the diverticulitis disease market’s progression. Factors such as unhealthy eating habits, a sedentary lifestyle, rampant obesity rates, genetic predispositions, and a growing aged population contribute to diabetes prevalence. This escalates the risk of complications like weakened blood vessels, making the colon more susceptible to infections and inflammations and pushing the demand for treatments and therapies higher. A notable example is NHS England’s report in June 2024 stating that prediabetes cases had risen to 3,615,330 in 2023, marking an 18% increase from 3,065,825 in 2022. Moreover, the under-40 age cohort saw a near 25% growth in diabetes incidences, from 173,166 in 2022 to 216,440 in 2023. Therefore, diabetes prevalence is undoubtedly a key driver of the diverticulitis disease market.

How is the global diverticulitis disease market divided into key segments?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Who are the key firms paving the way for growth in the diverticulitis disease market?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Which trends are expected to transform the diverticulitis disease market?

Leading firms in the diverticulitis disease market are focusing on creating novel drugs and securing their approval in order to maintain their market dominance. Advancing in drug development could establish more efficient therapies for diverticulitis, lessen the probability of complications, and enhance patient prognosis. For example, in April 2023, the US Food and Drug Administration, a federal entity based in the United States, gave its sanction to Seres’ microbiota medication designed to treat recurrent bowel infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and above. The clearance for Vowst came following a clinical trial that included 346 patients with recurrent CDI. The trial concluded that those who received Vowst had a significantly lower chance of experiencing a relapse of the infection compared to those who were given a placebo. This orally-administered drug is built upon microbiota composed of Firmicutes spores, which are recognised for creating a healthy microbiome that can stave off C. diff. colonisation.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

What regions are contributing significantly to the growth of the diverticulitis disease market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Antacids Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antacids-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Diverticulitis Disease Market Shape Industry Trends by 2034?

The market size for the diverticulitis disease has seen a swift expansion over the past few years. It is projected to rise from $1.85 billion in 2024 to $2.04 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The growth previously observed can be linked to factors such as an aging population, dietary practices, obesity, and advancements in medical imaging technology.

The market size for diverticulitis disease is predicted to exhibit robust growth in the coming years. It’s expected to increase to $2.92 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 9.4%. The surge during the forecasted period can be credited to factors such as endoscopy and colonoscopy, a heightened sense of awareness, less invasive operation procedures, and individualized treatments. The major trends anticipated in this period incorporate preventive strategies, improved diagnosis tools, cooperative healthcare models, and alterations in healthcare policies.

Which Drivers Are Expected to Have the Greatest Impact on the diverticulitis disease Market’s Growth?

The escalating trend of smoking is predicted to spur the development of the diverticulitis disease market. This increase in smoking habits stems from compelling advertising, its acceptance in society, stress, and the addictive characteristics of nicotine. The proliferation of e-cigarettes and vape devices, as well as social influences and peer pressure among the young, contribute to the skyrocketing rates of smoking. Smoking elevates the risk of developing diverticular disease by weakening the colon’s blood flow, leading to graver complications; this fosters a greater need for diagnosis and treatment methods. For example, in July 2022, Statistics Canada reported a 5.8% increase in cigarette production compared to June 2021. Furthermore, the total cigarette sales recorded a 1.3% boost from May 2022, achieving 1.4 billion in June 2022. Consequently, the increasing smoking prevalence is playing a key role in diverticulitis disease market’s expansion. A surge in diabetes incidence is projected to instigate further growth in the diverticulitis disease market. This rise can primarily be attributed to factors such as unhealthy diets laden with processed foods, sedentary lifestyles, escalating obesity rates, genetic factors, and an aging population. Diabetes exacerbates the risk of complications such as weakened blood vessels, making the colon more vulnerable to infections and inflammation, thereby increasing the need for various treatments and therapies. To illustrate, NHS England reported that as of June 2024, the figure for people identified as pre-diabetic rocketed to 3,615,330 in 2023, marking an upswing of 18% from 3,065,825 in 2022. Of note were the alarming numbers in the under 40 demographic, which saw almost a 25% increase, with cases ballooning from 173,166 in 2022 to 216,440 in 2023. Bearing this data in mind, one can assert that the escalating prevalence of diabetes is fuelling the growth of the diverticulitis disease market.

Get Your Free Sample of the Global Diverticulitis Disease Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Who Are the Key Market Players Influencing the Growth of the Diverticulitis Disease Industry?

Major companies operating in the diverticulitis disease market are:

• Pfizer Inc._x000D_

• Johnson and Johnson_x000D_

• F. Hoffmann-La Roche AG_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

What Key Market Trends Are Shaping the Future of the Diverticulitis Disease Industry?

Leading companies in the diverticulitis disease market are focusing on producing creative drugs and obtaining necessary approvals to maintain their market position. Through drug invention, more effective treatments for diverticiculitis can be achieved, minimizing the possibilities of complications and enhancing patient results. For example, Seres’ microbiota drug for recurrent gut infections was approved by the US-based federal organization, the United States Food and Drug Administration, in April 2023. The medicine aims to treat persistent gut infections and prevent the reappearance of Clostridioides difficile (C. diff.) infections in adults who are at least 18 years old. The authorization for Vowst was granted following a clinical trial involving 346 patients with recurrent CDI. Results showed that patients administered with Vowst had a significant decrease in the risk of infection recurrence compared to those given a placebo. The drug, administered orally, is comprised of microbiota with Firmicutes spores, which contribute to a healthy microbiome capable of resisting C. diff. colonization.

Get Instant Access to the Global Diverticulitis Disease Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Diverticulitis Disease Market?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids

4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Which Regions Are Emerging as Leaders in the Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Defining Features of the Diverticulitis Disease Market?

Diverticulitis disease refers to a medical condition characterized by inflammation or infection of small pouches that develop in the walls of the colon or large intestine. The symptoms of diverticular disease include lower abdominal pain, constipation, diarrhea and rectal bleeding.

Browse Through More Similar Reports By The Business Research Company:

Digestive Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Antacids Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antacids-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: